Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

Raised transaminases (hepatocellular injury)

Gastroenterology and hepatology · Abnormal laboratory result · updated 2026-10-31

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: Scotland: a quarter of adults have liver function tests over 10 years, of whom about a third with at least one abnormal value [1]

ALT or AST < 5 × ULN, without severity signs

Fasting sample.

Fasting laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

ALT or AST between 5 and 15 × ULN (without severity signs)

Rapid laboratory tests (within the next few days)

Detailed explanation and international comparison (in French): read it in English (machine translation)

> 15 × ULN, or low prothrombin time, jaundice, confusion: emergency

Detailed explanation and international comparison (in French): read it in English (machine translation)

Second-line tests (persistent hepatocellular injury, no cause found)

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Sources (8)
  1. Newsome PN, Cramb R, Davison SM, et al. Guidelines on the management of abnormal liver blood tests (British Society of Gastroenterology). Gut. 2018;67(1):6-19.
  2. Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017;112(1):18-35.
  3. Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 4124 (ARN du VHC), 4500-4501 (hépatite B), 8000 (mutation C282Y), 0350, 4502, 4503, 1807, 1809.
  4. Association française pour l'étude du foie (AFEF). Recommandations pour le diagnostic et le suivi non-invasif des maladies chroniques du foie (coord. V. de Lédinghen). Juillet 2020. Chapitre 4 : stéatopathie métabolique (J. Boursier).
  5. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obes Facts. 2024;17(4):374-444 (publication simultanée : J Hepatol. 2024;81(3):492-542, PMID 38851997).
  6. Langan RC, Hines-Smith KA. Mildly Elevated Liver Transaminase Levels: Causes and Evaluation. Am Fam Physician. 2024;110(6):585-591.
  7. Haute Autorité de santé. Actualisation des actes de biologie médicale relatifs au diagnostic et au suivi de l'hépatite E. Rapport d'évaluation technologique (argumentaire), juillet 2017.
  8. Goenner S, Corriat-Boutron A, Pelletier G, Legrand A, Buffet C. Macroaspartate aminotransférase. Étude de 5 cas et revue de la littérature. Gastroenterol Clin Biol. 1998;22(5):549-53.